Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, X.
Right arrow Articles by Nelson, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, X.
Right arrow Articles by Nelson, W. G.
[Cancer Research 61, 8611-8616, December 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Reversal of GSTP1 CpG Island Hypermethylation and Reactivation of {pi}-Class Glutathione S-Transferase (GSTP1) Expression in Human Prostate Cancer Cells by Treatment with Procainamide1

Xiaohui Lin, Kekule Asgari, Mathew J. Putzi, Wesley R. Gage, Xiang Yu, Brian S. Cornblatt, Arunima Kumar, Steven Piantadosi, Theodore L. DeWeese, Angelo M. De Marzo and William G. Nelson2

Departments of Oncology [X. L., K. A., W. R. G., X. Y., B. S. C., A. K., S. P., T. L. D., A. M. D., W. G. N.], Pathology [M. J. P., W. R. G., A. M. D., W. G. N.], Urology [T. L. D., A. M. D., W. G. N.], Pharmacology [W. G. N.], and Medicine [W. G. N.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231

Among the many somatic genome alterations present in cancer cells, changes in DNA methylation may represent reversible "epigenetic" lesions, rather than irreversible "genetic" alterations. Cancer cell DNA is typically characterized by increases in the methylation of CpG dinucleotides clustered into CpG islands, near the transcriptional regulatory regions of critical genes, and by an overall reduction in CpG dinucleotide methylation. The transcriptional "silencing" of gene expression associated with such CpG island DNA hypermethylation presents an attractive therapeutic target: restoration of "silenced" gene expression may be possible via therapeutic reversal of CpG island hypermethylation. 5-Aza-cytidine (5-aza-C) and 5-aza-deoxycytidine (5-aza-dC), nucleoside analogue inhibitors of DNA methyltransferases, have been widely used in attempts to reverse abnormal DNA hypermethylation in cancer cells and restore "silenced" gene expression. However, clinical utility of the nucleoside analogue DNA methyltransferase inhibitors has been limited somewhat by myelosuppression and other side effects. Many of these side effects are characteristic of nucleoside analogues that are not DNA methyltransferase inhibitors, offering the possibility that nonnucleoside analogue DNA methyltransferase inhibitors might not possess such side effects. Human prostate cancer (PCA) cells characteristically contain hypermethylated CpG island sequences encompassing the transcriptional regulatory region of GSTP1, the gene encoding the {pi}-class glutathione S-transferase (GSTP1), and fail to express GSTP1 as a consequence of transcriptional "silencing." Inactivation of GSTP1 by CpG island hypermethylation, the most common somatic genome alteration yet reported for human PCAs, occurs early during human prostatic carcinogenesis and results in a loss of GSTP1 "caretaker" function, leaving prostate cells with inadequate defenses against oxidant and electrophile carcinogens. We report here that the drug procainamide, a nonnucleoside inhibitor of DNA methyltransferases, reversed GSTP1 CpG island hypermethylation and restored GSTP1 expression in LNCaP human PCA cells propagated in vitro or in vivo as xenograft tumors in athymic nude mice.




This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
B. J. Evison, R. A. Bilardi, F. C. K. Chiu, G. Pezzoni, D. R. Phillips, and S. M. Cutts
CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity
Nucleic Acids Res., October 1, 2009; 37(19): 6355 - 6370.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
W. G. Nelson, A. M. De Marzo, and S. Yegnasubramanian
Epigenetic Alterations in Human Prostate Cancers
Endocrinology, September 1, 2009; 150(9): 3991 - 4002.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
N. Hokaiwado, F. Takeshita, A. Naiki-Ito, M. Asamoto, T. Ochiya, and T. Shirai
Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells
Carcinogenesis, June 1, 2008; 29(6): 1134 - 1138.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. S Perry, R. Foley, K. Woodson, and M. Lawler
The emerging roles of DNA methylation in the clinical management of prostate cancer.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. H. Lee, S. Yegnasubramanian, X. Lin, and W. G. Nelson
Procainamide Is a Specific Inhibitor of DNA Methyltransferase 1
J. Biol. Chem., December 9, 2005; 280(49): 40749 - 40756.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Lyko and R. Brown
DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies
J Natl Cancer Inst, October 19, 2005; 97(20): 1498 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. C. Chuang, C. B. Yoo, J. M. Kwan, T. W.H. Li, G. Liang, A. S. Yang, and P. A. Jones
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine
Mol. Cancer Ther., October 1, 2005; 4(10): 1515 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Brueckner, R. Garcia Boy, P. Siedlecki, T. Musch, H. C. Kliem, P. Zielenkiewicz, S. Suhai, M. Wiessler, and F. Lyko
Epigenetic Reactivation of Tumor Suppressor Genes by a Novel Small-Molecule Inhibitor of Human DNA Methyltransferases
Cancer Res., July 15, 2005; 65(14): 6305 - 6311.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Miyamoto and T. Ushijima
Diagnostic and Therapeutic Applications of Epigenetics
Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 293 - 301.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. R. Hodge, B. Peng, J. C. Cherry, E. M. Hurt, S. D. Fox, J. A. Kelley, D. J. Munroe, and W. L. Farrar
Interleukin 6 Supports the Maintenance of p53 Tumor Suppressor Gene Promoter Methylation
Cancer Res., June 1, 2005; 65(11): 4673 - 4682.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. J. Frey
Methylation of CpG islands: potential relevance for hypertension and kidney diseases
Nephrol. Dial. Transplant., May 1, 2005; 20(5): 868 - 869.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. W. Laird
Cancer epigenetics
Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R65 - R76.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L.-C. Li, P. R. Carroll, and R. Dahiya
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. Kopelovich, J. A. Crowell, and J. R. Fay
The Epigenome as a Target for Cancer Chemoprevention
J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Villar-Garea, M. F. Fraga, J. Espada, and M. Esteller
Procaine Is a DNA-demethylating Agent with Growth-inhibitory Effects in Human Cancer Cells
Cancer Res., August 15, 2003; 63(16): 4984 - 4989.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Xing, H. Usadel, Y. Cohen, Y. Tokumaru, Z. Guo, W. B. Westra, B. C. Tong, G. Tallini, R. Udelsman, J. A. Califano, et al.
Methylation of the Thyroid-stimulating Hormone Receptor Gene in Epithelial Thyroid Tumors: A Marker of Malignancy and a Cause of Gene Silencing
Cancer Res., May 1, 2003; 63(9): 2316 - 2321.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. C. Cheng, C. B. Matsen, F. A. Gonzales, W. Ye, S. Greer, V. E. Marquez, P. A. Jones, and E. U. Selker
Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine
J Natl Cancer Inst, March 5, 2003; 95(5): 399 - 409.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. C. Reinhold, H. Kouros-Mehr, K. W. Kohn, A. K. Maunakea, S. Lababidi, A. Roschke, K. Stover, J. Alexander, P. Pantazis, L. Miller, et al.
Apoptotic Susceptibility of Cancer Cells Selected for Camptothecin Resistance: Gene Expression Profiling, Functional Analysis, and Molecular Interaction Mapping
Cancer Res., March 1, 2003; 63(5): 1000 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Lin and W. G. Nelson
Methyl-CpG-binding Domain Protein-2 Mediates Transcriptional Repression Associated with Hypermethylated GSTP1 CpG Islands in MCF-7 Breast Cancer Cells
Cancer Res., January 15, 2003; 63(2): 498 - 504.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Bakker, X. Lin, and W. G. Nelson
Methyl-CpG Binding Domain Protein 2 Represses Transcription from Hypermethylated pi -Class Glutathione S-Transferase Gene Promoters in Hepatocellular Carcinoma Cells
J. Biol. Chem., June 14, 2002; 277(25): 22573 - 22580.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.